Piramal acquires solid oral dosage drug product facility from G&W Laboratories22 Jun 2020
The site can also produce liquids, creams, and ointments, further expanding the CDMO's portfolio.
Piramal Enterprises Limited's (PEL) Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), has signed an agreement with G&W Laboratories to acquire its solid oral dosage drug product manufacturing facility located in Sellersville, Pennsylvania, USA.
This acquisition broadens the offering of Piramal Pharma Solutions (PPS) by adding solid oral dosage form capabilities (tablets and capsules) in North America.
Until now, PPS' capabilities in solid oral dosage forms were located in the UK and India. The Sellersville site, which is FDA- and EMA-certified, can also produce liquids, creams, and ointments, further expanding the PPS portfolio.
The acquired site also can support product and process development for solid oral dosage and oral liquids, including immediate release, modified release, chewable and sublingual solid oral dosage forms, solutions and suspensions in liquids. The site has received certifications from the FDA and EMA.
"Many of our customers are looking for US-based manufacturing partners to expand and support their pipeline. This acquisition strengthens our ability to partner with them on best-in-class drug products. It enhances our services offering by adding a solid oral dosage capability in the US. We now offer solid oral drug product development and commercial manufacturing in all our major geographies, addressing a previously unmet customer need," said Peter DeYoung, CEO, PPS.
The Sellersville site covers 31.5 acres of land with over 221,000 sq. ft of manufacturing space, including 195,000 sq. feet of GMP area. The site features dedicated manufacturing and packaging technologies for solid oral dosage forms, liquids, creams, and ointments; quality control and microbiology labs; state-of-the-art preformulation and analytical development infrastructure coupled with a pilot lab for research and development; and a temperature-controlled warehouse.
The site currently has the necessary controls to support manufacturing of potent solid oral dosage forms. PPS intends to offer high potency drug manufacturing capabilities at the site, complementing the company's global strength in highly potent compounds.
SGS joins with Biophytis to launch international trial of COVID-19 related respiratory failure treatment
7 Jul 2020
The CRO will undertake this clinical trial at multiple sites worldwide, starting at the AZ Sint Maarten hospital in Mechelen, Belgium.Read more
Regeneron wins $450 million US government manufacturing agreement for anti-viral antibody cocktail
7 Jul 2020
The company began scaling up manufacturing of REGN-COV2 at business risk earlier this year to ensure the immediate availability of the product if clinical trials prove successful.Read more
Ajinomoto introduces fast track platform for drug product manufacturing
30 Jun 2020
AJILITY is designed to speed novel or existing therapeutics from development to manufacturing and into the clinic.Read more
Catalent and ViralClear Pharmaceuticals partner on potential COVID-19 treatment
22 Jun 2020
The CDMO will work on developing a solution and a solid oral dosage form of ViralClear's merimepodib.Read more
Sanofi to build EUR 490 million vaccine production facility in France
16 Jun 2020
The French pharma company will also invest EUR 120 million to create a new research center at Marcy-l'Etoile dedicated to vaccinesRead more
Vektor Pharma finalizes formula for novel transdermal drug delivery system to treat Parkinson's
8 Jun 2020
Optimizing the dosage form's efficiency reduces the amount of drug required in each patch.Read more
Emergent bags $628 million "landmark" CDMO deal to produce COVID-19 vaccine candidates
2 Jun 2020
The company will provide CDMO capabilities, capacities, and expertise to support the US government’s Warp Speed Program to pave the way for innovators to advance COVID-19 programs.Read more
Changes needed to prevent controversial pay-for-delay pharma deals
26 May 2020
Researchers endorse a switch from the current first-filer system in the US to a system that instead rewards the first successful challenger.Read more
SeraNova and Carna Biosciences to develop oral formulation of a new active ingredient
26 May 2020
SeraNovo enters into a second license agreement with Carna Biosciences for development of oral formulation of Carna’s kinase inhibitor.Read more
AbCellera and Lilly seal multi-year antibody discovery collaboration
25 May 2020
AbCellera, will use its antibody drug discovery platform to identify antibodies against up to nine targets.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation